VRTX vs. REGN, BMY, SNY, GSK, ZTS, PFE, TAK, ABT, RPRX, and BGNE
Should you be buying Vertex Pharmaceuticals stock or one of its competitors? The main competitors of Vertex Pharmaceuticals include Regeneron Pharmaceuticals (REGN), Bristol-Myers Squibb (BMY), Sanofi (SNY), GSK (GSK), Zoetis (ZTS), Pfizer (PFE), Takeda Pharmaceutical (TAK), Abbott Laboratories (ABT), Royalty Pharma (RPRX), and BeiGene (BGNE). These companies are all part of the "pharmaceutical preparations" industry.
Vertex Pharmaceuticals (NASDAQ:VRTX) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, community ranking, media sentiment and analyst recommendations.
Vertex Pharmaceuticals received 59 more outperform votes than Regeneron Pharmaceuticals when rated by MarketBeat users. Likewise, 75.65% of users gave Vertex Pharmaceuticals an outperform vote while only 66.58% of users gave Regeneron Pharmaceuticals an outperform vote.
91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. Comparatively, 83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. 0.2% of Vertex Pharmaceuticals shares are owned by company insiders. Comparatively, 8.8% of Regeneron Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
In the previous week, Vertex Pharmaceuticals and Vertex Pharmaceuticals both had 27 articles in the media. Regeneron Pharmaceuticals' average media sentiment score of 0.73 beat Vertex Pharmaceuticals' score of 0.70 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the news media.
Regeneron Pharmaceuticals has higher revenue and earnings than Vertex Pharmaceuticals. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Vertex Pharmaceuticals currently has a consensus target price of $429.45, suggesting a potential upside of 8.04%. Regeneron Pharmaceuticals has a consensus target price of $977.77, suggesting a potential upside of 10.71%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Regeneron Pharmaceuticals is more favorable than Vertex Pharmaceuticals.
Vertex Pharmaceuticals has a net margin of 36.68% compared to Regeneron Pharmaceuticals' net margin of 30.14%. Vertex Pharmaceuticals' return on equity of 21.91% beat Regeneron Pharmaceuticals' return on equity.
Vertex Pharmaceuticals has a beta of 0.35, indicating that its stock price is 65% less volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.11, indicating that its stock price is 89% less volatile than the S&P 500.
Summary
Vertex Pharmaceuticals beats Regeneron Pharmaceuticals on 9 of the 17 factors compared between the two stocks.
Get Vertex Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for VRTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vertex Pharmaceuticals Competitors List
Related Companies and Tools
